144 related articles for article (PubMed ID: 7882335)
1. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth.
Arap W; Nishikawa R; Furnari FB; Cavenee WK; Huang HJ
Cancer Res; 1995 Mar; 55(6):1351-4. PubMed ID: 7882335
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells.
Fueyo J; Gomez-Manzano C; Yung WK; Clayman GL; Liu TJ; Bruner J; Levin VA; Kyritsis AP
Oncogene; 1996 Jan; 12(1):103-10. PubMed ID: 8552379
[TBL] [Abstract][Full Text] [Related]
3. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
Ueki K; Ono Y; Henson JW; Efird JT; von Deimling A; Louis DN
Cancer Res; 1996 Jan; 56(1):150-3. PubMed ID: 8548755
[TBL] [Abstract][Full Text] [Related]
4. Transformation of human glioma cell lines with the p16 gene inhibits cell proliferation.
Hama S; Sadatomo T; Yoshioka H; Kurisu K; Tahara E; Naruse I; Heike Y; Saijo N
Anticancer Res; 1997; 17(3C):1933-8. PubMed ID: 9216647
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro.
Chintala SK; Fueyo J; Gomez-Manzano C; Venkaiah B; Bjerkvig R; Yung WK; Sawaya R; Kyritsis AP; Rao JS
Oncogene; 1997 Oct; 15(17):2049-57. PubMed ID: 9366522
[TBL] [Abstract][Full Text] [Related]
6. Loss of P16INK4 expression is frequent in high grade gliomas.
Nishikawa R; Furnari FB; Lin H; Arap W; Berger MS; Cavenee WK; Su Huang HJ
Cancer Res; 1995 May; 55(9):1941-5. PubMed ID: 7728764
[TBL] [Abstract][Full Text] [Related]
7. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
[TBL] [Abstract][Full Text] [Related]
8. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells.
Brenner AJ; Aldaz CM
Cancer Res; 1995 Jul; 55(13):2892-5. PubMed ID: 7796417
[TBL] [Abstract][Full Text] [Related]
9. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines.
Liu Q; Neuhausen S; McClure M; Frye C; Weaver-Feldhaus J; Gruis NA; Eddington K; Allalunis-Turner MJ; Skolnick MH; Fujimura FK
Oncogene; 1995 Mar; 10(6):1061-7. PubMed ID: 7700630
[TBL] [Abstract][Full Text] [Related]
10. Mutation rate of the CDKN2 gene in malignant gliomas.
Giani C; Finocchiaro G
Cancer Res; 1994 Dec; 54(24):6338-9. PubMed ID: 7987825
[TBL] [Abstract][Full Text] [Related]
11. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
Reed JA; Loganzo F; Shea CR; Walker GJ; Flores JF; Glendening JM; Bogdany JK; Shiel MJ; Haluska FG; Fountain JW
Cancer Res; 1995 Jul; 55(13):2713-8. PubMed ID: 7796391
[TBL] [Abstract][Full Text] [Related]
12. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
Ono Y; Tamiya T; Ichikawa T; Kunishio K; Matsumoto K; Furuta T; Ohmoto T; Ueki K; Louis DN
J Neuropathol Exp Neurol; 1996 Oct; 55(10):1026-31. PubMed ID: 8857999
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.
Herman JG; Merlo A; Mao L; Lapidus RG; Issa JP; Davidson NE; Sidransky D; Baylin SB
Cancer Res; 1995 Oct; 55(20):4525-30. PubMed ID: 7553621
[TBL] [Abstract][Full Text] [Related]
14. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas.
Fueyo J; Gomez-Manzano C; Bruner JM; Saito Y; Zhang B; Zhang W; Levin VA; Yung WK; Kyritsis AP
Oncogene; 1996 Oct; 13(8):1615-9. PubMed ID: 8895506
[TBL] [Abstract][Full Text] [Related]
15. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.
Pollock PM; Pearson JV; Hayward NK
Genes Chromosomes Cancer; 1996 Feb; 15(2):77-88. PubMed ID: 8834170
[TBL] [Abstract][Full Text] [Related]
16. Increased p16 levels correlate with pRb alterations in human urothelial cells.
Yeager T; Stadler W; Belair C; Puthenveettil J; Olopade O; Reznikoff C
Cancer Res; 1995 Feb; 55(3):493-7. PubMed ID: 7834615
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression.
Geradts J; Kratzke RA; Niehans GA; Lincoln CE
Cancer Res; 1995 Dec; 55(24):6006-11. PubMed ID: 8521382
[TBL] [Abstract][Full Text] [Related]
18. Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis.
Luca M; Xie S; Gutman M; Huang S; Bar-Eli M
Oncogene; 1995 Oct; 11(7):1399-402. PubMed ID: 7478563
[TBL] [Abstract][Full Text] [Related]
19. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
Moulton T; Samara G; Chung WY; Yuan L; Desai R; Sisti M; Bruce J; Tycko B
Am J Pathol; 1995 Mar; 146(3):613-9. PubMed ID: 7887443
[TBL] [Abstract][Full Text] [Related]
20. Deletion of p16INK4A/CDKN2 and p15INK4B in human somatic cell hybrids and hybrid-derived tumors.
Kuerbitz SJ; Malandro J; Compitello N; Baylin SB; Graff JR
Cell Growth Differ; 1999 Jan; 10(1):27-33. PubMed ID: 9950215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
